Feb 10 (Reuters) - Tempest Therapeutics TPST.O:
TEMPEST GRANTED FAST TRACK DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR AMEZALPAT TO TREAT PATIENTS WITH HEPATOCELLULAR CARCINOMA
Source text: ID:nGNX5h7lh8
Further company coverage: TPST.O